This new article publication from Acta Pharmaceutica Sinica B, discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a ...
Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...
The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial. The Food and Drug Administration (FDA) has granted Fast Track designation to BNC210 for the acute treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results